We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
RecipharmCobra Biologics and KAHR Medical Announce Continuation of Partnership in the Development of KAHR-102
News

RecipharmCobra Biologics and KAHR Medical Announce Continuation of Partnership in the Development of KAHR-102

RecipharmCobra Biologics and KAHR Medical Announce Continuation of Partnership in the Development of KAHR-102
News

RecipharmCobra Biologics and KAHR Medical Announce Continuation of Partnership in the Development of KAHR-102

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "RecipharmCobra Biologics and KAHR Medical Announce Continuation of Partnership in the Development of KAHR-102"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

RecipharmCobra Biologics, and KAHR Medical Ltd., that develops novel drugs based on the Signal Converter Proteins (SCP) technology for the treatment of cancer and autoimmune diseases, have announced a continuation of their partnership agreement.

Under the terms of the agreement, RecipharmCobra Biologics will continue to advance KAHR-102 for future pre-clinical and clinical testing using RecipharmCobra’s maxXpress service.

Peter Coleman, General Manager at RecipharmCobra Biologics, said: “We are extremely pleased that our development partnership continues with KAHR. Our partnership with KAHR has strengthened over the years due to the strong working relationship between both technical teams and we look forward to its continuation. It is an endorsement of the working relationship we invest in with our customers.”

Dr. Noam Shani, CEO of KAHR Medical, said “It has been a pleasure working with RecipharmCobra Biologics over the years and we have enjoyed the interaction and responsiveness of its team. We hope to build on our successful partnership with the fast-track development of KAHR-102.”

Advertisement